ProPhase Labs, Inc.

UNIONDALE, NY · CIK 0000868278 · Biotech · Public

Whole genome sequencing platform and cancer diagnostics/therapeutics development

prophaselabs.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$8.4M
4 Form D · Aug 2025
14 months since last filing
Contracts
—
No federal contracts on record
Patents
6
3 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$2,923,200
Private capital raisedForm D · SEC$1,500,000
Private capital raisedForm D · SEC$1,000,000
Private capital raisedForm D · SEC$3,000,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1449Thetis Pharmaceuticals LLC—$14M
1450PANDOMEDX, INC.——
1451COMETA THERAPEUTICS INC——
1452ProPhase Labs, Inc.—$8.4M
1453Surf Lakes Global, Inc.—$720K
1454Aion Therapeutic Inc.—$5.9M
1455Nistron, L.L.C.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 13 related persons
  • CAROLINA ABENANTEDirector
  • Jason BarrDirector
  • Mark BurnettDirector
  • Robert Cuddihy, Jr.Executive Officer
  • John DeShazoDirector
  • Mark FrankDirector
  • LOUIS GECKELDirector
  • Louis GleckelDirector
  • WARREN HIRSCHDirector
  • Ted KarkusDirector · Executive Officer
  • TED KARKUSDirector · Executive Officer
  • Mark LeventhalDirector
  • James McCubbinDirector

Patents

USPTO · 3 granted of 6

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.